Peptides8 min read
Why research-labelled SS-31 cannot borrow Forzinity’s label
Forzinity's approval applies to a defined prescription product and indication. Learn why an SS-31 name or purity claim cannot establish equivalence.
Read articleBlog
Research, explained. Explore peptides, supplements and hormone health with clear, practical breakdowns of what the studies actually tell us.
Peptides articles
All articlesMetabolism, recovery and emerging research
Peptides8 min read
GHRP-6 in stroke trials: what the hospital combination showed
The larger EGF–GHRP-6 stroke trial missed its main endpoint. Understand the early pilot, subgroup findings, safety and limits for recovery after stroke.
Read article
Peptides9 min read
Gonadorelin pumps and real-world access: why delivery is part of the evidence
Pulsatile gonadorelin depends on a complete delivery and monitoring program. A listed drug or historical approval does not establish access to the required pump.
Read article
Peptides9 min read
Why oxytocin's social effects depend on the people and the setting
Trust-game findings, a recent preregistered study and social-comparison experiments explain why context matters in oxytocin research.
Read article
Peptides9 min read
Pemvidutide for alcohol use disorder: what RECLAIM found
RECLAIM reported fewer heavy-drinking days with pemvidutide. Understand the phase 2 findings, their safety context and what still needs confirmation.
Read article
Peptides9 min read
Desmopressin in dogs: why treating thirst is not the same as diagnosing its cause
Dog studies show why a response to desmopressin must be interpreted alongside the cause of thirst, urine findings, blood sodium and follow-up.
Read article
Peptides8 min read
Can gonadorelin counter testosterone-related fertility suppression?
A pituitary response to gonadorelin does not establish fertility protection during testosterone therapy. Here is what the human evidence does and does not show.
Read article
Peptides9 min read
Peptide podcasts and the human-evidence gap: reading the Huberman–Bakri interview
Use the Huberman–Bakri peptide interview as a starting point for checking BPC-157 claims against rat experiments, small human reports and current regulatory evidence.
Read article
Peptides9 min read
What happens after tesamorelin stops?
Withdrawal studies show that tesamorelin’s visceral-fat reduction is not reliably permanent. Durability and a follow-up plan belong in the first conversation.
Read article
Peptides8 min read
Oxytocin in childbirth and wellness sprays: why the evidence differs
Oxytocin's established obstetric role depends on a specific product, purpose and monitoring setting. A wellness spray asks a different treatment question.
Read article
Peptides8 min read
Melanotan I and afamelanotide: why the product matters
Why an approved afamelanotide implant is not interchangeable with a tanning vial or spray, even when a label names the same peptide.
Read article
Peptides8 min read
Tirzepatide and food noise: what did researchers actually measure?
A closer look at test meals, appetite scales and brain research behind claims that tirzepatide quiets food noise.
Read article49–60 of 320 articles